Fondazione Ricerca Traslazionale

This phase 2 trial is testing a combination of the targeted drug amivantamab plus chemotherapy (pemetrexed or gemcitabine) in 33 people with advanced non-small cell lung cancer that has a specific EGFR exon20 insertion mutation. Participants have not had prior treatment and are n…

This phase II trial tests whether adding OSE2101 (TEDOPI®) to standard maintenance therapy with cemiplimab can better clear cancer DNA from the blood in people with advanced non-small cell lung cancer. The study enrolls 160 participants who have a specific immune type (HLA-A2 pos…

This study tests a combination of chemotherapy and immunotherapy (tislelizumab) given before surgery for people with stage III PD-L1 positive non-small cell lung cancer. The goal is to see if this approach helps more patients have successful surgery to remove all cancer. About 30…

This phase 2 trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help people with stage III non-small-cell lung cancer whose disease has returned after initial treatment. It also explores adding the targeted drug olaparib to durvalumab for ce…

This study is for people with non-small cell lung cancer who are about to start immunotherapy. Researchers want to see if the body makes antibodies against the immunotherapy drugs. By collecting blood samples from 270 participants, they hope to learn more about how the immune sys…